About Us
Immix Biopharma, Inc. (ImmixBio, Nasdaq: IMMX) is a clinical-stage biopharmaceutical company developing innovative cell therapies for AL amyloidosis and other autoimmune diseases.
Its lead candidate, NXC-201, is a next-generation CAR-T cell therapy being evaluated in the Phase 1b/2 NEXICART-1 clinical trial. The therapy has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for AL amyloidosis and multiple myeloma, as well as from the European Commission for AL amyloidosis. ImmixBio is also investigating NXC-201’s potential to offer a shorter duration of cytokine release syndrome (CRS), which could support faster patient recovery and broader applications in autoimmune diseases.
For more information, visit www.immixbio.com and www.BeProactiveInAL.com.
